Farnesyl pyrophosphate synthase modulators: A patent review (2006 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 9, 2011, Pages 1433-1451

  Sun, Shuting ^a   McKenna, Charles E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bisphosphonate; Bone diseases; Cancer therapeutics; Farnesyl pyrophosphate synthase; Fluorescent imaging probes; Infectious diseases; Malaria; Osteoporosis

Indexed keywords

(PYRIDINIUM 1 YL)ETHYL 1,1 DIPHOSPHONIC ACID DERIVATIVE; (QUINOLINIUM 1 YL) 1,1 DIPHOSPHONIC ACID DERIVATIVE; 1 FLUORO 2 (7 METHYL)IMIDAZO[1,2 A]PYRIDIN 3 YLETHYLBISPHOSPHONIC ACID; 2 (6 FLUORO)IMIDAZO[1,2 A]PYRIDIN 3 YLETHYLBISPHOSPHONIC ACID; 2 (7 METHYL)IMIDAZO[1,2 A]PYRIDIN 3 YLETHYLBISPHOSPHONIC ACID; 2 (IMIDAZO[1,2 A]PYRIDIN 3 YL)ETHYLBISPHOSPHONIC ACID; 2 AZABICYCLO[4.3.0]NONANE 8,8 DIPHOSPHONIC ACID; 2 ETHYLIMIDAZO[1,2 A]PYRIDIN 3 YL)METHYLBISPHOSPHONIC ACID; 2 HYDROXY 2 PHOSPHONO 3 (PYRIDIN 3 YL)PROPANOIC ACID; 2 HYDROXY 3 (IMIDAZO[1,2 A]PYRIDIN 3 YL) 2 PHOSPHONOPROPIONIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BPH 715; CARBOXYLIC ACID DERIVATIVE; CLODRONIC ACID; FLUORO 2 (IMIDAZO[1,2 A]PYRIDIN 3 YL)ETHYLBISPHOSPHONIC ACID; GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; INDOLE DERIVATIVE; MEVALONIC ACID; MINODRONIC ACID; NE 10790; PAMIDRONIC ACID; PHOSPHONOCARBOXYLATE DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; QUINOLINE DERIVATIVE; RISEDRONIC ACID; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ALZHEIMER DISEASE; BIOLOGICAL ACTIVITY; BONE METASTASIS; BONE MINERAL; BONE TUMOR; CANCER INVASION; DRUG FORMULATION; DRUG LEGISLATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DYSPNEA; ENZYME SUBSTRATE; FLUORESCENCE IMAGING; HAIR DISEASE; HUMAN; HYPERTENSION; LIPOPHILICITY; METASTASIS; NEOPLASM; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PARASITOSIS; PATENT; PROTEIN EXPRESSION; REVIEW; SKIN DISEASE; SOFT TISSUE DISEASE; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TREATMENT INDICATION; TUMOR GROWTH;

ANIMALS; BONE RESORPTION; CHEMISTRY, PHARMACEUTICAL; DIPHOSPHONATES; GERANYLTRANSTRANSFERASE; HUMANS; MEVALONIC ACID; PATENTS AS TOPIC; PHOSPHONIC ACIDS; QUINOLINES; SALICYLIC ACIDS;

EID: 80052075924     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.593511     Document Type: Review

References (87)

1. Ogura K, Koyama T. Enzymatic aspects of isoprenoid chain elongation. Chem Rev 1998;98:1263-76
2. Liang PH, Ko TP, Wang AH. Structure, mechanism and function of prenyltransferases. Eur J Biochem 2002;269:3339-54
3. Szkopinska A, Plochocka D. Farnesyl diphosphate synthase; regulation of product specificity. Acta Biochim Pol 2005;52:45-55 (Pubitemid 41132175)
4. Sacchettini JC, Poulter CD. Creating isoprenoid diversity. Science 1997;277:1788-9 (Pubitemid 27449183)
5. Holstein SA, Hohl RJ. Isoprenoids: remarkable diversity of form and function. Lipids 2004;39:293-309 (Pubitemid 38971743)
6. Lynen F, Agranoff BW, Eggerer H, et al. Gamma-gamma-dimethyl- allylpyrophosphate and geranyl-pyrophosphate, biological preliminary stages of squalene. 6. biosynthesis of terpenes. Angew Chem Int Ed 1959;71:657-63
7. Liang PH. Reaction kinetics, catalytic mechanisms, conformational changes, and inhibitor design for prenyltransferases. Biochemistry 2009;48:6562-70
8. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004;229:567-85 (Pubitemid 38878903)
9. Moreno SN, Li ZH. Anti-infectives targeting the isoprenoid pathway of Toxoplasma gondii. Expert Opin Ther Targets 2008;12:253-63 (Pubitemid 351419420)
10. Wiemer AJ, Hohl RJ, Wiemer DF. The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med Chem 2009;9:526-42
11. Wiemer AJ, Hsiao CH, Wiemer DF. Isoprenoid metabolism as a therapeutic target in gram-negative pathogens. Curr Top Med Chem 2010;10:1858-71
12. van Beek E, Pieterman E, Cohen L, et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11 (Pubitemid 29500472)
13. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006;103:7829-34
14. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-76 (Pubitemid 30484516)
15. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42 (Pubitemid 32112446)
16. Hosfield DJ, Zhang Y, Dougan DR, et al. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 2004;279:8526-9 (Pubitemid 38295905)
17. Rondeau JM, Bitsch F, Bourgier E, et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006;1:267-73 (Pubitemid 43700307)
18. Russell RGG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59
19. Roelofs AJ, Thompson K, Ebetino FH, et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010;16:2950-60
20. Dunford JE. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition. Curr Pharm Des 2010;16:2961-9
21. McKenna CE, Kashemirov BA, Bonaz-Krause PI. Preparation and use of alpha-keto phosphonates. US7462733; 2008
22. McKenna CE, Kashemirov BA, Sanchez GV. Alpha-hydroxy, alpha-substituted methylenebisphosphonates and phosphonoacetates. US20080200679; 2008
23. Mustafa DA, Kashemirov BA, McKenna CE. Microwave-assisted synthesis of nitrogen-containing 1-hydroxymethylenebisphosphonate drugs. Tetrahedron Lett 2011;52:2285-7
24. Sanders JM, Song Y, Chan JMW, et al. Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases. WO2006039721; 2006
25. Sanders JM, Song Y, Chan JMW, et al. Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases. US7358361; 2008
26. Sanders JM, Song Y, Chan JMW, et al. Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases. US7745422; 2010
27. Sanders JM, Song Y, Chan JMW, et al. Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases. US20100316676; 2010
28. Martin MB, Arnold W, Heath HT, et al. Nitrogen-containing bisphosphonates as carbocation transition state analogues for isoprenoid biosynthesis. Biochem Biophys Res Commun 1999;263:754-8 (Pubitemid 29490699)
29. Ohno K, Mori K, Orita M, et al. Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem 2011;18:220-33
30. Ebetino FH, Roze CN, McKenna CE, et al. Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. J Organomet Chem 2005;690:2679-87 (Pubitemid 40597308)
31. Oldfield E, Song Y, Zhang Y, et al. Bisphosphonate compounds and methods. WO2007109585; 2007
32. Oldfield E, Song Y, Zhang Y, et al. Bisphosphonate compounds and methods. US7687482; 2010
33. Oldfield E, Zhang Y, Yin F. Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS. WO2008128056; 2008
34. Oldfield E, Zhang Y. Bisphosphonate compounds and methods with enhanced potency for multiply targets including FPPS, GGPPS, and DPPS. US20080255070; 2008
35. Zhang YH, Cao R, Yin F, et al. Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc 2009;131:5153-62
36. Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130-46 (Pubitemid 24379702)
37. Sanders JM, Gomez AO, Mao J, et al. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J Med Chem 2003;46:5171-83 (Pubitemid 37414187)
38. Szabo CM, Matsumura Y, Fukura S, et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem 2002;45:2185-96 (Pubitemid 34525798)
39. Guo RT, Cao R, Liang PH, et al. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci USA 2007;104:10022-7 (Pubitemid 47175256)
40. Ebetino FH, Mazur A, Lundy MW, et al. 4-azaindole bisphosphonates. WO2010033980; 2010
41. Ebetino FH, Mazur A, Lundy MW, et al. 5-azaindole bisphosphonates. WO2010033981; 2010
42. Ebetino FH, Boeckman RK Jr, Song X. (1r,6s)-2-azabicyclo[4.3.0] nonane-8,8-diphosphonic acid and its use in treating or preventing bone disorders, for example, osteoporosis or Paget's disease. WO2008076417; 2008
43. Ebetino FH, Boeckman RK Jr, Song X. Composition for treating bone disorders. US7781418; 2010
44. Ebetino FH, Mazur A, Lundy MW, et al. Imidazo[1,2-alpha]pyridinyl bisphosphonates. WO2010033978; 2010
45. Marma MS, Xia Z, Stewart C, et al. Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem 2007;50:5967-75
46. Weiler S, Widler L, Rondeau J-M, et al. C2-C5-alkyl-imidazole bisphosphonates. WO2009068567; 2009
47. Ebetino FH, Dansereau SM. Bisphosphonate antiresorptive structure-activity relationships. In: Bijvoet O, Fleisch HA, Canfield RE, Russell G. editors. Bisphosphonates on Bones. Elsevier Science B.V; Amsterdam: 1995. p. 139-53
48. Deprele S, Kashemirov BA, Hogan JM, et al. Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5Hcyclopenta[ c]pyridin-7-yl(hydroxy) methylene]bis(phosphonic acid) (NE-10501): synthetic, structural, and modeling studies. Bioorg Med Chem Lett 2008;18:2878-82 (Pubitemid 351608881)
49. Dunford JE, Kwaasi AA, Rogers MJ, et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008;51:2187-95 (Pubitemid 351503274)
50. McKenna CE, Kashemirov BA, Blazewska KM, et al. Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a ]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem 2010;53:3454-64
51. Coxon FP, Helfrich MH, Larijani B, et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 2001;276:48213-22
52. Coxon FP, Ebetino FH, Mules EH, et al. Phosphonocarboxylate inhibitors ofRab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 2005;37:349-58 (Pubitemid 41160493)
53. Baron RA, Tavare R, Figueiredo AC, et al. Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase. J Biol Chem 2009;284:6861-8
54. Blazewska KM, Ni F, Haiges R, et al. Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors. Eur J Med Chem; In press; DOI: 10.1016/j.ejmech. 2011.04.063
55. Guo Z, Wu YW, Das D, et al. Structures of RabGGTase-substrate/ product complexes provide insights into the evolution of protein prenylation. EMBO J 2008;27:2444-56
56. Tan KT, Guiu-Rozas E, Bon RS, et al. Design, synthesis, and characterization of peptide-based rab geranylgeranyl transferase inhibitors. J Med Chem 2009;52:8025-37
57. Cotesta S, Glickman JF, Jahnke W, et al. Salicyclic acid derivatives being farnesyl pyrophosphate synthase activity inhibitors. WO2010043584; 2010
58. Amstutz R, Bold G, Cotesta S, et al. Quinolines as inhibitors of farnesyl pyrophosphate synthase. WO2009106586; 2009
59. Jahnke W, Rondeau JM, Cotesta S, et al. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nat Chem Biol 2010;6:660-6
60. Frost GI. Combination therapy using a soluble hyaloronidase and a bisphosphonate. WO2009128918; 2009
61. Zanetti D, Cairatti D, Piccinni E, et al. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof. US7560490; 2009
62. van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res 1984;238:355-8 (Pubitemid 14025016)
63. Seiler P, Aichele P, Odermatt B, et al. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol 1997;27:2626-33 (Pubitemid 27453853)
64. Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003;14:1430-7 (Pubitemid 37185291)
65. Johnson EM, Johnson ME. Microparticle compositions to modify cancer promoting cells. US20090215729; 2009
66. Frost GI. Combination therapy using a soluble hyaluronidase and a bisphosphonate. US20090311237; 2009
67. Ashton P. Implantable formulations of bisphosphonic acids. US20100247607; 2010
68. Beltz K, Lustenberger P, Petersen H. Pharmaceutical composition with bisphosphonate. WO2009121935; 2009
69. Beltz K, Lustenberger P, Petersen H. Pharmaceutical composition with bisphosphonate. US20110034418; 2011
70. Levy N, Cau P, Lopez-Otin C. Combination of an HMG-CoA reductase inhibitor and a farnesyl pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins. WO2008003864; 2008
71. Levy N, Cau P, Lopez-Otin C. Use of HMG-CoA reductase and farnesyl pyrophosphate synthase inhibitors for the preparation of a medicine. US20100120720; 2010
72. Okamura H, Kubo S, Li WV. Gamma.9V.Delta.2 t cell proliferation agent, method for producing activated v.gamma.9v.delta.2 t cells, and uses thereof. US7749760; 2010
73. McCormack PL, Plosker GL. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs 2006;66:711-28 (Pubitemid 43671458)
74. Keating GM, Scott LJ. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone. Drugs 2007;67:793-804 (Pubitemid 46535649)
75. Linares GE, Rodriguez JB. Current status and progresses made in malaria chemotherapy. Curr Med Chem 2007;14:289-314
76. Cau P, Bourgeois P, Bonniol V, et al. Composition and methods used during anti-HIV treatment. US20110046091; 2011
77. Bonniol V, Bourgeois P, Cau P, et al. Composition and methods used during anti-HIV treatment. WO2009115652; 2009
78. Bonniol V, Bourgeois P, Cau P, et al. Cosmetic and/or dermatological composition. WO2009112653; 2009
79. Bae E, Kim J, Kim J. Therapy for Alzheimer's disease. WO2007132292; 2007
80. Bae E, Kim J, Kim J. Therapy for Alzheimer's disease. WO2007015122; 2007
81. McKenna CE, Kashemirov BA, Bala JLF. Synthesis of drug conjugates via reaction with epoxide-containing linkers. US20080312440; 2008
82. Kashemirov BA, Bala JL, Chen X, et al. Fluorescently labeled risedronate and related analogues: magic linker synthesis. Bioconjug Chem 2008;19:2308-10
83. Sun S, Blazewska KM, Kashemirov BA, et al. Synthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs. Phosphorus Sulfur Silicon Relat Elem 2011;186:970-1
84. Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010;25:606-16
85. Satchi-Fainaro R, Miller K, Shabat D, et al. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases. WO2009141823; 2009
86. Satchi-Fainaro R, Segal E, Kopecek J, et al. A conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions. WO2009141827; 2009
87. Ebetino FH, Hogan AM, Sun S, et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011;49:20-33